Sorafenib-induced diarrhea and hypophosphatemia: Mechanisms and therapeutic implications

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 280-281

  Mir, O ^a   Coriat, R ^a   Boudou rouquette, P ^a   Durand, J P ^a   Goldwasser, F ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; ESOMEPRAZOLE; PANCREAS ENZYME; PARATHYROID HORMONE; SORAFENIB;

ADULT; AGED; CALCIUM URINE LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LETTER; LIVER CELL CARCINOMA; MELANOMA; MUSCLE ATROPHY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SARCOMA; STEATORRHEA; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 84855177596     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr525     Document Type: Letter

References (5)

1. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
2. Bellini E, Pia A, Brizzi MP et al. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism. Ann Oncol 2011; 22: 988-990.
3. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23: 965-972.
4. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-5772.
5. Antoun S, Baracos VE, Birdsell L et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594-1598.